Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
The Oncologist|December 28, 2022
Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib TrialJames Larkin, Mototsugu Oya, Marcella Martignoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2010
Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recoveryKrishna S Gunturu, Kenneth R Meehan, Todd A Mackenzie, et al.
The Lancet. Oncology|March 14, 2018
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trialToni K Choueiri, James Larkin, Mototsugu Oya, et al.
Cancer Journal (Sudbury, Mass.)|January 22, 2014
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United StatesLawrence Flaherty, Omid Hamid, Gerald Linette, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2003
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trialJoseph I Clark, Michael B Atkins, Walter J Urba, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal AntibodyNeil H Segal, Theodore F Logan, F Stephen Hodi, et al.
ESMO Open|November 28, 2020
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trialLaurence Albiges, Nizar M Tannir, Mauricio Burotto, et al.
Cancer Cell|November 6, 2020
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis BlockadeRobert J Motzer, Romain Banchereau, Habib Hamidi, et al.
The New England Journal of Medicine|April 21, 2015
Nivolumab and ipilimumab versus ipilimumab in untreated melanomaMichael A Postow, Jason Chesney, Anna C Pavlick, et al.
European Urology|November 9, 2021
First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 TrialLaurence Albiges, Nizar M Tannir, Mauricio Burotto, et al.
Pageof 6